Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04677049 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Niacin in Glioblastoma

Name: Study of Niacin in Glioblastoma — clinical trial record (NCT04677049)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorAHS Cancer Control Alberta

Started2021-03-18

View on ClinicalTrials.gov ↗

This is a single institution Phase I-II study to evaluate the tolerability and Maximum Tolerated Dose (MTD) (Phase I) and efficacy (Phase II) of adding Niacin CRT™ to standard first line treatment (concurrent Radiation Therapy (RT) and Temozolomide (TMZ) following by monthly TMZ - AKA Stupp protocol) in patients with newly diagnosed glioblastoma isocitrate dehydrogenase (IDH) wild type.

Amendment history 3 changes detected by DataLookout

2026-09-04

Trial status changed: Suspended → Active, Not Recruiting

2026-09-04

Primary completion pushed: 2026-12-31 → 2027-12

2026-09-04

Completion pushed: 2026-12-31 → 2027-12

Trial Details

NCT Number	NCT04677049
Lead Sponsor	AHS Cancer Control Alberta Collaborators: Tom Baker Cancer Centre
Conditions	Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Enrollment	59 participants
Start Date	2021-03-18
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-03